OS Therapies Incorporated
OSTX
$1.68
$0.021.21%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 457.80% | 876.99% | 574.51% | 254.13% | 23.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 293.34% | 377.93% | 184.93% | 56.91% | 1.59% |
| Operating Income | -293.34% | -377.93% | -184.93% | -56.91% | -1.59% |
| Income Before Tax | -148.55% | -121.18% | -52.64% | -14.00% | 17.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -148.55% | -121.18% | -52.64% | -14.00% | 17.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -148.55% | -121.18% | -52.64% | -14.00% | 17.15% |
| EBIT | -293.34% | -377.93% | -184.93% | -56.91% | -1.59% |
| EBITDA | -288.66% | -375.03% | -185.21% | -56.99% | -1.65% |
| EPS Basic | 2.81% | 24.65% | 31.31% | 21.88% | 35.86% |
| Normalized Basic EPS | 12.87% | 32.58% | 37.64% | 28.97% | 35.60% |
| EPS Diluted | 2.81% | 24.65% | 31.31% | 21.88% | 35.86% |
| Normalized Diluted EPS | 12.87% | 32.58% | 37.64% | 28.97% | 35.60% |
| Average Basic Shares Outstanding | 159.55% | 200.05% | 137.28% | 57.22% | 24.90% |
| Average Diluted Shares Outstanding | 159.55% | 200.05% | 137.28% | 57.22% | 24.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |